With the unprecedented recent past finally behind us, we look forward to shaping the year ahead as a glorious landmark by pioneering innovation, quality benchmarking, tactical expansion and sustained growth. Today, as drug development becomes more complex, factors like cost, quality and timelines have become the yardsticks by which CROs are being evaluated. With our highly evolved expertise, comprehensive services, broad experience and an elite list of clientele, we are poised to capitalize on this scenario and accelerate our growth story.

While expanding our dominance in the Indian CRO landscape, we are poised to build upon our strong presence in the US CRO industry by enhancing our Oncology and Biosimilar Late Phase Clinical Trials capabilities. Lambda's recent emphasis has been on meeting the needs of biotechnology-derived therapies development utilizing our cutting-edge, regulatory-compliant bioanalytical-biosimilar laboratory. Our global technical teams and SMEs continue to nurture new ideas for the development of novel therapeutics encouraging pharmaceutical innovation and drug repurposing.

Continually underpinning our quality promise, in the last 5 years, we have successfully faced 60+ International Inspections/Audits, 140+ sponsor Audits and 1000+ monitoring audits. We also enjoy having the distinction of all our submitted dossiers being approved till date without any concerns. With our expanding global footprint, we are well-positioned to create benchmarks and shape the future of the clinical research industry by ensuring quality, reliability, and value-added services. Looking ahead, we are currently aiming at revenues of USD 130 million by the FY 2025-26.

As we usher in a promising New Year, I take this opportunity to wish you a peaceful and prosperous New Year and look forward to strengthening our esteemed association.

Best Regards,
Bindi Chudgar